Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Tolemy Bio secures €1.4M in pre-seed funding to enhance its AI-driven cell biology research technology, led by Norrsken Evolve.
PRIVATEMay 12, 2026•2 months ago
Amount Raised
€1.4 Million
Round Type
Seed
Cambridge
Investors
A New Uk Based Stealth FundMasiaJme VenturesBig Sur VenturesNorrsken Evolve
Description
Cambridge-based Tolemy Bio has raised €1.4 million in pre-seed funding to advance its AI-enabled technology for cell biology research. The funding will be used to expand data generation and machine learning capabilities, as well as support early customer deployments. The round was led by Norrsken Evolve with participation from multiple investors. Tolemy Bio aims to optimize the fragmented workflows in biopharma and cell biology using its platform, Orbit.
Company Information
Company
Tolemy Bio
Location
Cambridge, England, United Kingdom
About
Tolemy Bio is a biotech startup that focuses on AI-enabled technology for cell biology research and biopharma development. The company is developing Orbit, a system designed to help researchers better understand and optimize living cells used in modern therapies. Tolemy Bio aims to streamline experimental workflows, which are currently fragmented and manual, to enhance the application of AI tools in drug development. The company's ultimate goal is to create a virtual-cell platform that facilitates more precise and data-driven experimentation in biopharma.
Cambridge